基于mTOR信号通路的靶向抗肝癌研究进展

Research progress in m TOR-targeted therapy for hepatocelluar carcinoma

m TOR信号通路高表达于肝癌并参与其多种恶性生物学行为,是治疗的潜在靶点,但单一使用m TOR抑制剂能抑制免疫功能,并反馈性激活m TOR上游分子Akt诱导抵抗。m TOR抑制剂联合其他药物能通过协同效应克服上述不足,是抗肝癌治疗的新策略。

Aberrant mammalian target of rapamycin （mTOR） signaling has a critical role in the pathogenesis of hepatocellular carcinoma （HCC） and is a potential target.The effects of mTOR inhibitors used as single agent on HCC are limited due to immunosuppression and resistance induced by paradoxical activation of Akt.Combined use of mTOR inhibitors and other anticancer agents synergistically improves the outcome of treatment for HCC,and may be a promising therapeutic strategy.